{"id":"W2996090129","doi":"10.1158/1078-0432.ccr-19-1638","title":"A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer","year":2019,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":90,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Juravinski Cancer Centre; Princess Margaret Cancer Centre","funders":"National Cancer Institute; V Foundation for Cancer Research","keywords":"Carboplatin; Gemcitabine; Internal medicine; Medicine; Topotecan; Neutropenia; Ovarian cancer; Clinical endpoint; Oncology; Leukopenia; Phases of clinical research; Chemotherapy; Cancer; Gastroenterology; Clinical trial; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00146147,0.001302463,0.00193985,0.000331847,0.0003787119,0.0008521147,0.0007413013,0.001508202,0.005368322],"category_scores_gemma":[0.001336465,0.000552181,0.0009369709,0.0003804733,0.001003137,0.0007110141,0.0004057561,0.002697935,0.0006842473],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009224192,"about_ca_system_score_gemma":0.001517808,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009950403,"about_ca_topic_score_gemma":0.001875937,"domain_scores_codex":[0.9995397,0.0002558238,0.00002187892,0.00008892005,0.00002378257,0.00006985041],"domain_scores_gemma":[0.9990501,0.0002164942,0.0001889333,0.00008674583,0.00004774578,0.0004100575],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9653398,0.01369667,0.001086377,0.0002200986,0.0004001676,0.00005846856,0.00005275509,0.0004845097,0.005160788,0.0001059345,0.0009088184,0.01248563],"study_design_scores_gemma":[0.921455,0.07569549,0.001289608,0.000009917924,0.0001335609,0.00003639147,0.00001454002,0.0003885863,0.0004716406,0.00008847762,0.0004095362,0.000007196154],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9925939,0.001002575,0.0003474499,0.0005270945,0.0002373742,0.003588244,0.0005217621,0.00006290595,0.001118626],"genre_scores_gemma":[0.9896342,0.0007166294,0.001050838,0.001146889,0.0002246423,0.003908616,0.001080974,0.00001972842,0.002217584],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005368322,"threshold_uncertainty_score":0.01795882,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.113838503015016,"score_gpt":0.4829287768198101,"score_spread":0.369090273804794,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}